arrow
A

Alberto Fabbri

University of Siena
H指数:31
被引数:5,128

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Secondary Genetic Events and Their Relationship to TP53 Mutation in Mantle Cell Lymphoma: A Sub-Study from the FIL_MANTLE-FIRST BIO on Behalf of Fondazione Italiana Linfomi (FIL)

次级遗传事件及其与Mantle Cell Lymphoma中TP53突变的关系:一项来自FIL_MANTLE-FIRST BIO的亚组研究,代表意大利淋巴瘤基金会(FIL)

Cancers
IF4.4
2026-03-040
OAAI
A Fondazione Italiana Linfomi cohort study of R-COMP vs R-CHOP in older patients with diffuse large B-cell lymphoma
2023-08-015
OAAI
Validity of Italian administrative healthcare data in describing the real-world utilization of infusive antineoplastic drugs: the study case of rituximab use in patients treated at the University Hospital of Siena for onco-haematological indications
2023-05-311
OAAI
Role of Rituximab Addition to First-line Chemotherapy Regimens in Nodular Lymphocyte-predominant Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi
2023-04-014
OAAI
Ibrutinib in relapsed/refractory patients with Waldenstrom macroglobulinemia: a real-life, retrospective study on behalf of the RTL (regional Tuscan lymphoma network)
2023-02-031
PRE
Real-world Outcomes of Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based Therapy
2022-12-017
OAAI
Diffuse large B-cell lymphoma in octogenarians aged 85 and older can benefit from treatment with curative intent: a report on 129 patients prospectively registered in the Elderly Project of the Fondazione Italiana Linfomi (FIL)
2022-11-1713
OAAI
The elderly prognostic index predicts early mortality in older patients with diffuse large B-cell lymphoma. An ad hoc analysis of the elderly project by the Fondazione Italiana Linfomi
2022-10-077
PRE
IgM-secreting diffuse large B-cell lymphoma: results of a multicentre clinicopathological and molecular study
LEUKEMIA
IF13.4
2022-09-205
PRE
Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial
LEUKEMIA
IF13.4
2022-05-1380
PRE
Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real-life experience
2021-11-017
OAAI
Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana Linfomi
2021-07-302
PREAI
Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study (vol 64, pg 589, 2020)
LEUKEMIA
IF13.4
2021-01-223
OAAI
Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study
LEUKEMIA
IF13.4
2020-08-1163
PREAI
Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation

来那度胺维持治疗不适合自体移植或移植失败的复发性弥漫性大b细胞淋巴瘤患者的长期疗效和安全性

2020-05-058
PREAI
MYC protein expression scoring and its impact on the prognosis of aggressive B-cell lymphoma patients
2018-06-2828
OA
Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi
2018-05-1055
OAAI